New Treatment Approaches To Indolent Non-Hodgkin’s Lymphoma
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference26 articles.
1. Non-Hodgkin’s lymphoma;Multani;Curr Pharm Biotechnol,2001
2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma;McLaughlin;J Clin Oncol,1998
3. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma;Davis;J Clin Oncol,1999
4. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma;Davis;J Clin Oncol,2000
5. Rituximab in indolent lymphoma:;McLaughlin;Semin Oncol,1999
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in thyroid cancer and identifies less-aggressive tumours;British Journal of Cancer;2014-06-17
2. Antibody Phage Display Libraries: Contributions to Oncology;International Journal of Molecular Sciences;2012-05-04
3. Prevention of hepatitis B virus reactivation under rituximab therapy;Immunotherapy;2009-11
4. Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions;Clinical Cancer Research;2009-10-27
5. The Impact of High-dose Sodium Selenite Therapy on Bcl-2 Expression in Adult Non-Hodgkin’s Lymphoma Patients: Correlation with Response and Survival;Biological Trace Element Research;2007-05-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3